CCRC - Certified Clinical Research Coordinator Participant Safety & AE Reporting Questions and Answers — Questions and Answers
Question 1: A study participant in a clinical trial for a new hypertension medication reports a persistent, severe headache. The headache is listed in the Investigator's Brochure as a possible side effect. According to ICH GCP guidelines, how should this event be classified?
- As a Serious Adverse Event (SAE) because it is severe.
- As an Adverse Event (AE). (Correct answer)
- As an Unanticipated Problem Involving Risks to Subjects or Others (UPIRSO).
- As a protocol deviation since the event was expected.
Correct answer: As an Adverse Event (AE).
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Since the headache is a medical occurrence during the trial, it is an AE. It is not an SAE because it does not meet the criteria for seriousness (e.g., life-threatening, requiring hospitalization). Severity (severe headache) is not the same as seriousness. It is not a UPIRSO because the event was anticipated (listed in the Investigator's Brochure). It is not a protocol deviation, but rather a clinical event to be documented and reported per protocol.
Question 2: A Clinical Research Coordinator (CRC) is notified that a study participant has been hospitalized due to a suspected reaction to the investigational drug. According to FDA regulations for IND trials, what is the maximum timeframe for the sponsor to report this unexpected fatal or life-threatening suspected adverse reaction to the FDA?
- Within 24 hours of the site becoming aware of the event.
- Within 10 working days.
- As soon as possible, but no later than 7 calendar days. (Correct answer)
- No later than 15 calendar days.
Correct answer: As soon as possible, but no later than 7 calendar days.
FDA regulation 21 CFR 312.32(c)(2) requires sponsors to notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible, but in no case later than 7 calendar days after the sponsor's initial receipt of the information. The 15-day timeframe applies to other serious and unexpected suspected adverse reactions.
Question 3: Which of the following is a primary responsibility of the Clinical Research Coordinator (CRC) in the management of adverse events?
- Determining the final causality assessment of the event.
- Informing the FDA directly of all Serious Adverse Events.
- Ensuring accurate and timely documentation of the event in the source documents and Case Report Forms (CRFs). (Correct answer)
- Modifying the protocol to mitigate future risks.
Correct answer: Ensuring accurate and timely documentation of the event in the source documents and Case Report Forms (CRFs).
The CRC plays a critical role in ensuring that all adverse events are accurately and promptly documented in the participant's source records and transcribed correctly onto the CRFs. While the CRC assists in collecting information, the Principal Investigator is ultimately responsible for the causality assessment. The sponsor, not the site CRC, is responsible for reporting SAEs to the FDA. Protocol modifications are the responsibility of the sponsor.
Question 4: During a Phase III trial, a participant experiences an allergic reaction resulting in anaphylactic shock, which requires emergency intervention and hospitalization. This specific type of reaction was not previously identified in the Investigator's Brochure. This event should be categorized as a:
- Serious Adverse Event (SAE) only.
- Suspected Unexpected Serious Adverse Reaction (SUSAR). (Correct answer)
- Non-serious Adverse Drug Reaction (ADR).
- Protocol Violation.
Correct answer: Suspected Unexpected Serious Adverse Reaction (SUSAR).
This event is a SUSAR because it meets all three criteria: It is Serious (life-threatening, requires hospitalization), Unexpected (not listed in the Investigator's Brochure), and a suspected Adverse Reaction (a causal relationship is suspected). While it is an SAE, the more specific and complete classification is SUSAR, which triggers expedited reporting to regulatory authorities by the sponsor.
Question 5: What key factor distinguishes a 'Serious Adverse Event' (SAE) from a non-serious adverse event according to ICH GCP guidelines?
- The severity grade of the event (e.g., mild, moderate, severe).
- The outcome or consequence of the event meeting specific criteria. (Correct answer)
- The certainty of the event's relationship to the investigational product.
- The frequency of the event's occurrence within the study population.
Correct answer: The outcome or consequence of the event meeting specific criteria.
An SAE is defined by its outcome. According to ICH E6 and FDA definitions, an event is serious if it results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment. Severity is a separate scale and does not automatically make an AE serious. Relatedness and frequency are important for overall safety assessment but do not define 'seriousness'.
Question 6: A research participant reports feeling nauseous after taking the investigational product. The CRC reviews the protocol and informed consent form, noting that nausea is a known and expected side effect. What is the CRC's most appropriate immediate next step?
- Report the event to the IRB as an Unanticipated Problem within 24 hours.
- Instruct the participant to immediately discontinue the investigational product.
- Document the event, including its severity and duration, in the participant's source document.
- Submit a Serious Adverse Event report to the sponsor. (Correct answer)
Correct answer: Submit a Serious Adverse Event report to the sponsor.
The CRC's immediate responsibility is to thoroughly document the clinical event in the source documentation. This includes details like onset, duration, severity, and any action taken. Since the event is expected and non-serious, it does not require immediate reporting to the IRB as an Unanticipated Problem or to the sponsor as an SAE. The decision to discontinue the product would be made by the Principal Investigator based on the event's severity and the protocol's guidance.
CCRC - Certified Clinical Research Coordinator Participant Safety & AE Reporting Questions and Answers
A study participant in a clinical trial for a new hypertension medication reports a persistent, severe headache.
The headache is listed in the Investigator's Brochure as a possible side effect.
According to ICH GCP guidelines, how should this event be classified?